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Chronic lymphocytic leukemia (CLL) T cells display largely defective anti-tumor 
responses. From a clinical perspective, there is a clear need to optimize CLL 
immunotherapy, especially regarding minimal residual disease eradication. Boosting 
anti-tumor T cell responses could ideally fit this gap, and identifying the best 
combination treatment partners is of translational relevance.  
We investigated the effect of treatment on CLL T cells in relation to: (i) treatment 
type (FCR versus ibrutinib versus rituximab-idelalisib), and (ii) clinical response. 
In contrast to chemoimmunotherapy, B-cell receptor signaling inhibitors (BcRi) 
preserved pre-treatment T cell clones, which expanded further as treatment 
continued and the clinical response deepened. We found major clonotypes shared 
among different patients, raising the possibility of selection by conserved, CLL-
associated epitopes. A concurrent restoration of T cell functionality with BcRi 
therapy arguably contributed to clinical response. Overall, this data provides 









Background: Using next-generation sequencing (NGS), we recently documented T 
cell oligoclonality in treatment-naive chronic lymphocytic leukemia (CLL), with 
evidence indicating T cell selection by restricted antigens.  
Experimental Design: Here, we sought to comprehensively assess T cell repertoire 
changes during treatment in relation to: (i) treatment type [fludarabine-
cyclophosphamide-rituximab (FCR) versus ibrutinib (IB) versus rituximab-idelalisib (R-
ID)], and (ii) clinical response, by combining NGS immunoprofiling, flow cytometry 
and functional bioassays.  
Results: T cell clonality significantly increased at: (i) 3 months in the FCR and R-ID 
treatment groups, and (ii) over deepening clinical response in the R-ID group, with a 
similar trend detected in the IB group. Notably, in constrast to FCR that induced T 
cell repertoire reconstitution, B cell receptor signaling inhibitors (BcRi) preserved 
pre-treatment clones. Extensive comparisons both within CLL as well as against T cell 
receptor sequence databases showed little similarity with other entities, but instead 
revealed major clonotypes shared exclusively by CLL patients, alluding to selection by 
conserved CLL-associated antigens. We then evaluated the functional effect of 
treatments on T cells and found that: (i) R-ID upregulated the expression of 
activation markers in effector memory T cells, and (ii) both BcRi improved anti-tumor 
T cell immune synapse formation, in marked contrast to FCR.  
Conclusions: Taken together, our NGS immunoprofiling data suggest that BcRi retain 





and immune synapse bioassays support a concurrent restoration of functionality, 







The tumor microenvironment (TME) plays a pivotal role in the natural course of 
chronic lymphocytic leukemia (CLL). This is evidenced by ample immunogenetic cues 
suggesting selection of the malignant B cell clone by a restricted set of antigens, as 
well as by the remarkable clinical efficacy of drugs interfering with B-cell receptor 
signaling (BcR signaling inhibitors, BcRi).1-6 Although BcRi were developed to target 
the clonal B cells, accumulating data suggest a pleiotropic effect in the CLL 
microenvironment, particularly T cells, which may contribute to their clinical 
efficacy.7-15 
T cells are intimately implicated in CLL pathophysiology. Xenograft studies have 
highlighted the importance of trophic signals provided by T cells for the survival of 
the malignant clone.16 On the other hand, immunosurveillance by T cells is 
compromised in CLL, due to, amongst others, defective cytoskeletal signaling and 
lytic immune synapse formation following tumor immunosuppressive signaling.17-20 
Therefore, delineating the mechanisms driving T cell tolerance rather than effective 
anti-tumor cytotoxic immune responses is highly relevant and could facilitate 
optimization of immunotherapy for CLL, with the aim of eradicating minimal residual 
disease.21, 22   
Studies employing different methodologies have demonstrated the existence of T 
cell expansions in CLL.23-27 Recently, we investigated the role of antigenic stimulation 
in shaping the T cell repertoire in treatment-naive CLL using next-generation 
sequencing (NGS).28 Our study confirmed T cell oligoclonality, with major (high-





clonotypes shared among different patients, which appeared to be CLL-specific. 
Overall, these findings pointed towards selection of T cells by CLL-associated 
antigenic epitopes. 
On these grounds, we sought to comprehensively assess the effect of treatment on 
CLL T cell repertoire dynamics by combining NGS immunogenetics, flow cytometry 
and immune synapse bioassays, in order to investigate associations of quantitative 
and/or qualitative changes with the type of treatment and clinical response. 
Considering recent data about collateral effects of BcRi treatment on T cells,7-14, 29 we 
focused on patients receiving ibrutinib (IB) or rituximab-idelalisib (R-ID) which we 
compared to patients receiving standard chemoimmunotherapy with the 
fludarabine-cyclophospphamide-rituximab (FCR) regimen. 
In sharp contrast to chemoimmunotherapy, BcRi were found to preserve pre-
treatment T cell clones. These clones expanded further as treatment continued and 
clinical response deepened, particularly in the case of R-ID. Repertoire comparisons 
revealed major clonotypes shared by different CLL patients but very few “public” 
clonotypes (i.e. also present in other conditions), suggesting selection by conserved 
CLL-associated epitopes. Moreover, phenotypic and immune synapse bioassays 
supported a concurrent restoration of T cell functionality with BcRi therapy, mostly 
evident for R-ID, arguably contributing to clinical response. Taken together, this data 
provides a rationale for designing combination strategies aiming to boost cytotoxic 










We analyzed samples from 28 CLL patients treated in two centres (Thessaloniki, 
Greece; Milan, Italy) with FCR (n=9), IB (n=15), and/or R-ID (n=10). Patients were 
selected on the basis of sample availability. Demographic and clinicobiological 
characteristics are provided in Suppl. Table 1. For 22 patients, samples were 
collected over the 1st line of treatment, either FCR or BcRi. For the remaining 6/28 
patients, we analyzed samples collected over consecutive lines of treatment (1st line 
FCR/2nd line IB, n=3; 1st line FCR/2nd line R-ID, n=2; 1st line IB/2nd line R-ID, n=1). In all 
cases, samples post-treatment initiation were analyzed in relation to a respective 
pre-treatment initiation sample. In total, we analyzed 98 peripheral blood (PB) 
samples: (i) for patients who received FCR, we analyzed samples collected pre-
treatment (n=9) and at 3 months after the completion of the 6 cycles (n=9, all in 
complete remission); (ii) for patients who received BcRi, we analyzed samples pre-
treatment (n=25), at 3 months (n=25), 9 months (n=17), best clinical response 
(median 20 months, n=13)] while still on continuous BcRi treatment. Best response 
timepoint was defined by the attending physician, and corresponded to the maximal 
duration of BcRi treatment at the time the study was conducted (median time on 
BcRi treatment: 20 months), with the single exception of a patient who progressed 
on IB and proceeded to R-ID as 2nd line treatment. This patient was assessed only at 
the 3-month timepoint while on IB, at which he had achieved PR.  Also, we included 
6 bone marrow (BM) samples, collected along with the respective PB pre-treatment 





No patient had evidence of infection at sampling. All patients were negative for HBV 
DNA, anti-HCV and anti-HIV I/II. We carefully excluded patients who developed 
rituximab-related late-onset neutropenia (R-LON), as it is known to be mediated by 
cytotoxic T cell clones.30 The local Ethics Review Committee approved the study and 
written informed consent form was obtained from all individuals in accordance with 
the Declaration of Helsinki. 
 
Next-generation sequencing, definitions and interpretation 
TRBV-TRBD-TRBJ gene rearrangements were RT-PCR amplified and subjected to 
paired-end NGS (MiSeq, Illumina), as previously described.28 For all samples, the 
starting absolute T cell count exceeded 0.5x106 cells to ensure adequate repertoire 
profiling depth.  
Paired-end protocol allowed sequencing of the TRB complementarity-determining 
region 3 (CDR3) twice/read, thus increasing the accuracy of results. In order to 
further increase the accuracy of results, raw reads were processed through a 
purpose-built bioinformatics pipeline performing: (i) length/quality filtering of raw 
reads; (ii) merging of filtered-in paired reads via local alignment; (iii) length/quality 
filtering of stitched sequences.28 Detailed length, quality and overlap rules are 
provided in Suppl. Table 2. Importantly, no base calls of Q-score<30 were allowed in 
the 75 nucleotide stretch preceding the FGXG motif at the start of TRB FR4, thus 
further increasing the CDR3 sequencing reliability. Filtered-in sequences were 
submitted to IMGT/HighV-QUEST (http://www.imgt.org), and metadata was 
processed by a validated bioinformatics algorithm designed for clonotype 





TRBV-TRBD-TRBJ gene rearrangements with functional TRBV genes were included in 
the analysis. TRBV-TRBD-TRBJ gene rearrangements carrying TRBV genes with <95% 
germline identity were also discarded as sequences with unacceptable error rate, 
given the lack of somatic hypermutation in T cells. 
Clonotypes were computed as unique pairs of TRBV genes and CDR3 amino acid 
sequences within a sample. Clonotypes were considered expanded when they 
contained ≥2 sequences, otherwise they were considered as "singletons". The 10 
most expanded clonotypes within a sample are referred to as "major". The relative 
frequency of each clonotype/sample was calculated as the number of 
rearrangements corresponding to the clonotype divided by the total number of 
productive, filtered-in rearrangements for that particular sample.  
For TRB gene repertoire analysis, clonotypes rather than single rearrangements were 
considered in order to avoid potential biases due to expansion following antigenic 
stimulation, i.e. individual TRBV gene frequencies within a sample were calculated as 
the number of clonotypes using particular TRBV genes over the total number of 
clonotypes. Each category of samples (PBMCs, BM) was analyzed separately. 
 
Inter-patient and across entities clonotype comparison 
We determined the major clonotypes of all CLL samples included in the study (n=563 
unique clonotypes, i.e. 10 major clonotypes of each sample removing duplicate 
values such as clonotypes which persisted in overtime analysis of the same patient 
or clonotypes shared among different patients) and compared them across CLL 
patients of this cohort, and against: (i) all T cell clonotypes from our previous  NGS 





from 15 healthy donors (NGS study by our group,  n=573,651),32 (iii) HHV-4 (Ebstein-
Barr virus, EBV), HHV-5 (cytomegalovirus, CMV), and BK virus-specific T cell 
clonotypes (anti-viral T cell NGS study by our group, n=169,502),33 (iv) non-
redundant, well-annotated, unique T cell clonotypes retrieved from public databases 
(n=17,024),34, 35 and (v) T cell clonotypes from previous low-throughput 
immunoprofiling studies (classic subcloning followed by Sanger sequencing) in 
clinical monoclonal B cell lymphocytosis (high-count MBL, n=545),36 as well as clinical 
entities associated with clonal T cell expansions [R-LON (n=283),30 chronic idiopathic 
neutropenia (CIN, n=576),37 large granular T cell leukemia (Τ-LGL, n=932)].38-40  
 
Flow cytometry 
Multi-color flow cytometry (FACSCanto II cell analyzer, BD Biosciences) was 
performed to investigate the expression of activation and exhaustion markers (CD25, 
CD38, CD69, HLA-DR and PD1, respectively) in functionally distinct T cell 
subpopulations, namely: (i) CD4+ and CD8+ naive T cells (CD45RA+/CCR7+), (ii) CD4+ 
and CD8+ central memory T cells  (CM, CD45RO+/CCR7+), (iii) CD4+ and CD8+ effector 
memory T cells (EM, CD45RO+/CCR7-), and (iv) CD4+ and CD8+ terminal effector 
memory RA cells (TEMRA, CD45RA+/CCR7-). Eight patients (R-ID, n=4; IB, n=4) pre-
treatment and at the 3-month timepoint were analyzed, as shown in Figure 1A.  
Viably frozen peripheral blood mononuclear cells were thawed and resuspended in 
PBS (15 × 106 cells in 1 mL) and incubated with pretitrated Abs to cell-surface 
markers at 4°C for 20 minutes. CD45 V500, CD3 V450, CD4 PerCP, CD4 PE-Cy7, CD8 
PE-Cy7, CCR7 APC-Cy7, CD45RO FITC, CD45RA FITC, CD69 PE, CD25 APC, CD38 PerCP, 





by forward and side scatter, CD45 positive plus 7AAD negative staining. Data were 
analyzed using the Kaluza flow cytometry analysis software (Beckman Coulter) 
(Suppl. Fig. 1).  
An acquisition cut-off of 20,000 CD3+ live cells/sample was applied to ensure reliable 
representation of all studied T cell subpopulations, as well as uniformity across 
samples. For T cell activation/exhaustion analysis, results were expressed as the 
proportion of cells expressing antigens of interest (percent positive staining). 
 
Immune synapse bioassays,  confocal microscopy and quantitative image analysis 
Tumor cell-T cell conjugate assays were designed to test the ability of CLL T cells to 
form immune synapses with autologous tumor cells.  Negatively selected viable 
CD3+ T cells (1x106) from untreated, FCR- or BCRi-treated patients were conjugated 
with equal numbers of autologous CLL tumor cells acting as antigen presenting cells 
pulsed with super-antigen cocktail and stained with CMAC blue dye (ThermoFisher 
Scientific) according to the manufacturer’s instructions. Cell conjugates were 
incubated for 15min at 37°C, 5% CO2. Immunofluorescent labeling was done using 
Cytofuge2 cell concentrator, as described previously.19 Antibodies (Abs) for 
rhodamine phalloidin (F-actin staining) and perforin (Alexafluor 488 conjugated)  
were applied for 45 minutes at 4°C in 5% goat serum (Sigma-Aldrich) solution. After 
washing, cell specimens were sealed with 22×32 mm coverslips using fluorescent 
mounting (Dako). Images were captured with an A1R confocal microscope (Nikon) 
using a 63× oil objective with NIS- Elements software Version 5.01  imaging software 
(Nikon) and fluorescence was acquired sequentially. The specificity of staining was 





group) were analyzed using NIS-Elements software Version 5.01  to measure the F-
actin (red fluorescent channel) and perforin (green fluorescent channel) polarization 
at contact sites and immune synapses using relative recruitment index (RRI) analysis. 
RRI is calculated as the ratio of F-actin/perforin mean fluorescent intensity at the 
immune synapse area to the respective value at a cellular membrane area not 
involved in an immune synapse (RRI<1 indicates a non-polarized, dysfunctional 
immune synapse). RRI values were expressed as mean value +/- SEM. 
  
Statistical analysis and visualization tools 
Descriptive statistics for discrete parameters included counts and frequency 
distributions. The significance of bivariate/multivariate relationships between 
variables was assessed using the Student t-test, as well as the non-parametric 
Wilcoxon (for paired values) and Mann-Whitney tests. For all comparisons a 
significance level of p=0.05 was set.  
By applying the Wilcoxon-signed rank test for matched pairs, the power of the NGS 
analysis ranges from 92% (for the most populated comparison, i.e. pre-IB versus IB at 
3 months, n=15 samples) to 53% for the least populated comparisons, i.e.  pre-R-ID, 
R-ID at 3 months, R-ID at 9 months versus R-ID at best response, n=5 samples). A 
table with power values for each paired comparison is provided in Supplemental 
Material (Suppl. Table 3). 
All statistical analyses were performed using the statistical Package GraphPad Prism 
version 5.03 (GraphPad Software, Inc., San Diego, USA). For data visualization, either 
publicly available software (http://circos.ca, https://CRAN.R-project.org) or purpose-






Data Sharing Statement   
Raw sequence data have been submitted to the Sequence Read Archive (SRA); 








The T cell repertoire in CLL is skewed both pre- and post-treatment initiation in all 
treatment subgroups, with clonal expansions 
First, we profiled by NGS the TR gene repertoire in terms of clonality and TRB gene 
usage. Overall, 23,262,732 TRBV-TRBD-TRBJ sequences were obtained, of which 
20,347,768 (87.5%, median 155,479/sample) passed filters and were further 
analyzed. The median number of distinct clonotypes/sample was 11,420 (range: 
2672-54,045); the median number of expanded clonotypes and singletons/sample 
was 5287 (range: 772-26,501) and 6417 (range: 1500-32,428), respectively.  
All CLL patient blood samples showed a T cell oligoclonal profile. The median T cell 
clonality of all analyzed samples, calculated as the cumulative frequency of the 10 
major clonotypes/sample, was 37.5% (range 8.1-70.5%).  
Nine TRBV genes accounted for almost half of the total repertoire both pre-
treatment and at the 3-month timepoint (46.8% and 47.6% of the total repertoire, 
respectively). The relative frequency of each gene did not particularly differentiate 
over treatment, nor amongst treatment groups (FCR, IB, R-ID)(Suppl. Figure 2A). The 
single exception concerned the TRBV28 gene, which was underrepresented in the R-
ID group both pre-treatment and at the 3-month timepoint [3.0%/3.4% versus 
5.1%/5.1% in the FCR group (p<0.01) versus 4.5%/4.6% in the ΙΒ group (p<0.01), 
respectively]. For both the IB and the R-ID groups, where the repertoire was studied 
beyond the 3-month timepoint, the TRBV gene frequency remained relatively stable 





In conclusion, the T cell repertoire was skewed in all examined subgroups, with 
restricted TRB gene usage and significant clonal expansions.    
 
T cell clonality increases over treatment and may be associated to clinical response 
We then tested clonality dynamics over treatment and explored associations with 
clinical response. At cohort level (n=28 patients), circulating T cell clonality increased 
after treatment [median values from 30.3% pre-treatment to 38.8% (p<0.05), 41.9% 
(p<0.05) and 46.2% (p<0.01) at the 3-month, 9-month, and deepest clinical response 
timepoint, respectively].  
Within different treatment groups, T cell clonality increased at the 3-month 
timepoint in the case of FCR (from 28.8% to 46.9%, p<0.05) and R-ID (from 33.0% to 
39.1%, p<0.01), but not IB (from 33.3% to 31.2%, p: 0.99). For the IB and R-ID groups, 
longitudinal analysis over treatment showed a gradual increase of T cell clonality, 
related to the depth of clinical response, reaching statistical significance in the case 
of R-ID [from 33.0% pre-treatment to 39.1% at 3 months (p<0.01), 46.0% at 9 
months (p<0.01) and 46.1% at best clinical response (p: 0.13)], but not IB [from 
33.3% pre-treatment to 31.2% at 3 months (p: 0.99), 39.1% at 9 months (p: 0.44) and 
42.1% at best clinical response (p: 0.17)] (Figure 2).  
We also performed analyses where clonality definition was modified in order to 
include a larger proportion of the repertoire (calculated as the cumulative frequency 
of the 20 or 50 most expanded clonotypes/sample, instead of 10). These analyses, as 
well as plots of clonotype frequency in relation to its rank in the repertoire, showed 
that the gradual increase of clonality resulted from the expansion of the major 





Differential impact of chemoimmunotherapy versus BcRi on the T cell repertoire  
To further study clonal dynamics over treatment, we evaluated clonal persistence 
overtime for each treatment group. We found that chemoimmunotherapy (FCR) 
resulted in T cell repertoire renewal through ablation and immune reconstitution, 
whereas BcRi retained most major pre-treatment T cell clones (median number of 
major pre-treatment clonotypes that persisted at the 3-month timepoint: 2/10 for 
FCR versus 8/10 for ΙΒ versus 7/10 for R-ID) (Figure 3Α). Overlap analysis of the total 
repertoire pre- and post-treatment per group showed similar results (Figure 3Β). 
Furthermore, in the case of BcRi where the repertoire was studied longitudinally 
over treatment, repertoire preservation persisted over time  (Figure 3C). 
 
Clonotype comparisons document the existence of ‘disease-biased’ T cell 
clonotypes  
To obtain insight into the antigenic specificities of the expanded T cell clones, we 
next listed all unique major clonotypes from our cohort (n=563 clonotypes) and 
compared them (i) across patients, and (ii) against T cell clonotypes from various 
entities, as detailed in the Methods section. 
Thirty-two of the 563 clonotypes were shared among different CLL patients (Suppl. 
Table 4 ), while 18/563 were found in another entity and/or healthy donors ("public" 
clonotypes") (Figure 4). In particular, "public" clonotypes corresponded to 9 matches 
with T cell clonotypes of herpes virus specificity (CMV, EBV), 2 matches with 
clonotypes of herpes virus specificity (EBV) that were also found in patients with CIN, 
and 5 matches with T cell clonotypes from healthy donors. Importantly, of the 32 





whereas the remaining 23 (23/563, 4.1% of all major clonotypes of our cohort) were 
shared exclusively by CLL patients, alluding to selection by CLL-associated antigens 
("CLL-specific"). Of these 23 “CLL-specific” clonotypes, 3 were shared among 4 
different patients, 5 among three different patients, and the remaining 15 among 
pairs of patients. 
 
Major CLL-specific T cell clonotypes expand further over treatment  
Considering the above, we repeated our clonality analysis excluding all "public" 
clonotypes, with similar results. More specifically, clonality significantly increased at 
the 3-month timepoint in the case of FCR (from 20.8% to 46.9%, p<0.01) and R-ID 
(from 32.9% to 38.8%, p<0.01), but not ΙΒ (from 33.3% to 31.2%, p=0.50). Overtime, 
clonality increased in both the R-ID and IB group, however reaching statistical 
significance only in the former [R-ID: from 32.9% to 38.8% at 3 months (p<0.01), 
44.4% at 9 months (p<0.01) and 39.5% at best clinical response (p:ns); IB: from 
33.3% to 31.2% at 3 months (p:ns), 39.1% at 9 months (p:ns) and 42.1% at best 
clinical response (p:ns)] (Figure 5).  
 
Pre-treatment major T cell clonotypes from the peripheral blood are also found in 
the bone marrow  
For 6 patients (R-ID, n=3 and IB, n=3), synchronous pre-treatment PB and infiltrated 
BM samples were available. We performed pairwise comparison of the T cell 
repertoires, to investigate for the presence of PB major clonotypes within the 





these patients (n=56) were identified within the respective BM repertoires, and 
37/56 (66.0%) were listed among the major clonotypes/BM sample. 
 
Idelalisib-based therapy increases the expression of activation markers on effector 
memory T cells 
NGS immunoprofiling showed that T cell clonality increased with BcRis, with major 
clones persisting and further expanding over time. In some cases, these clones were 
shared among different CLL patients but not found in other entities, suggesting that 
they may have developed in response to CLL-specific antigens. Therefore, we next 
wanted to investigate the impact of treatment on T cell functionality, so as to 
uncover a possible link between these T cell expansions and anti-tumor responses 
that could contribute to the deepening of clinical response.  
To this end, we examined distinct T cell subsets of 8 patients (R-ID, n=4; IB, n=4) pre-
treatment and at 3 months for the expression of activation and exhaustion markers 
by flow cytometry. While the relative frequencies of these T cell subsets, namely 
CD4+ and CD8+ naive, central memory (CM), effector memory (EM) and terminal 
effector memory (TEMRA) T cells, did not significantly fluctuate over treatment (data 
not shown), the expression of activation markers significantly increased post-
treatment in the R-ID group compared to the IB group. More specifically, we noted 
increased expression of: (i) CD69 in CD4+ EM (median fold change 2.0 versus 0.5, 
p<0.01); (ii) CD25 in CD8+ TEMRA (median fold change 1.3 versus 0.5, p<0.01), and 
(iii) CD38 in CD8+ EM (median fold change 1.6 versus 0.3, p<0.05) and TEMRA Τ cells 






BcRi treatment improves T cell immune synapse formation with tumor cells  
Given that T cell dysfunction in CLL has been linked to impaired immune synapse 
formation, we finally investigated the impact of therapy on immune function by 
characterizing the ability of patient T cells to form synapse interactions with 
autologous baseline CLL cells in 13 patients pre-treatment and at 3 months (FCR, 
n=3; R-ID, n=5; IB, n=5). Confocal microscopy with quantitative image analysis 
showed that T cells from FCR-treated patients did not improve their ability to form 
synapse interactions (Figure 6A) whereas both BcRi increased the formation of 
polarized F-actin immune synapses with tumor cells (R-ID, IB, p<0.05; FCR, p=0.99) 
(Figure 6B and C). We also detected enhanced polarization of the cytolytic molecule 
perforin towards tumor cells in IB-associated T cell synapses (p<0.05) (Figure 6B). For 
2 patients (R-ID, n=1; IB, n=1), RRI immune synapse analysis was also performed at 
the deepest clinical response timepoint. These assays revealed no change in T cell 
synapse formation at the deepest response timepoint reached with IB therapy (25 
months) compared to the 3 month timepoint, that may suggest a normalization of T 
cell function. In contrast, for the patient who received R-ID, deeper clinical response 
(12 months) correlated with a further increase in polarized  immune synapse 








In the present work we sought to investigate the effect of different types of 
treatment on T cells from CLL patients. Given the pleiotropic impact of BcRi on the 
CLL microenvironment, we focused on BcRi as currently used for CLL treatment (IB 
and R-ID) and compared with standard chemoimmunotherapy (FCR).13 Our study 
cohort was significantly enriched for CLL cases with unmutated IGHV genes, the main 
reason being that these cases are most frequently in need of treatment, especially 
BcRis. While it cannot directly account for IGHV-mutated CLL, all reported findings 
concern pair-matched samples (samples of the same patient over time), therefore 
we argue that IGHV mutational status is not an influent.   
We report that T cell clonality significantly increased after treatment with FCR and 
over treatment with R-ID, and, at least in the case of R-ID, this correlated with the 
depth of clinical response, peaking at 9 months. A similar trend was detected with IB 
therapy, however an increase in clonality occurred later in the course of treatment 
(≥9mo) and did not reach statistical significance, possibly due to the smaller number 
of samples at more advanced timepoints.  
At first glance, the IB results may seem  contradictory to a recent study by Yin et al, 
reporting that IB therapy resulted in TR repertoire diversification, however, certain 
experimental and analytical differences may explain this.7 From the start, the use of 
different clonotype definitions renders the results incomparable: Yin et al reported 
outcomes on the 1000 most frequent clonotypes (defined as productive unique 
sequences per sample), while in the present study we focused on the 10 most 





the same IGHV gene. Moreover, Yin et al7 utilized the ImmunoSEQ platform by 
Adaptive Biotechnologies, whereas we applied customized, purpose-built 
bioinformatics algorithms with intentionally strict length and quality filtering. Of 
note, the increasing T cell repertoire diversity reported by Yin mostly results from an 
increasing number of singletons. When we performed the same type of analysis in 
our cohort, following clonotype definition as per the Yin et al study, we also found an 
increase of the singleton fraction at the 9-month timepoint, although not reaching 
statistical significance. Besides, Yin et al7 mention that 6/16 dominant TRBV-TRBJ 
usages persist and further expand over 12 months of IB therapy, and therefore 
speculate antigenic stimulation, in an analogy to our results. Finally, Yin et al7 
comment on repertoire diversity by focusing on the emergence of new low-
frequency clones over treatment, while, we, on the other hand, focus on the 
dynamics of the most frequent clones on the consideration that these are the most 
biologically relevant, and dwell into the hypothesis that may have expanded in 
response to tumor antigens. We do not comment on repertoire diversity; this may 
be associated with infectious risks and complications, as hypothesized by Yin et al, 
but is most probably irrelevant to the dynamics of anti-tumor clones. 
Somewhat expectedly, FCR increased T cell clonality through repertoire ablation and 
reconstitution, probably reflecting a lymphotoxic effect that is restored overtime. 
Indeed, in a patient who received FCR and was studied prospectively, the increase of 
clonality at 3 months post-treatment was restored to pre-treatment levels by 9 
months. In sharp contrast, BcRi did not reconstitute the T cell repertoire, retaining 
pre-treatment major T cell clones during therapy, and this was shown consistently 





In order to obtain evidence as to whether the herin identified T cell clones might 
have expanded in response to CLL-associated antigens or not, we performed 
extensive comparisons against not only CLL/MBL sequence datasets,36, 41 but also 
datasets from common herpes virus infections (CMV/EBV), healthy individuals, and 
entities mediated by T cell clones.30, 32-35, 37-40 and found a significant number of 
major T cell clonotypes shared exclusively among CLL patients. This is remarkable 
given: (i) the random HLA background of our cohort, and (ii) the size of the 
comparison dataset (761,968 distinct TRBV-TRBD-TRBJ sequences). Therefore, this 
finding supports the existence of (neo)epitopes that are conserved across CLL. Along 
the same line of reasoning, it is worth noting that, for 3 patients studied over 
sequential lines of treatment, we found major clonotypes prior to 1st line FCR which 
disappeared at CR following FCR treatment, but re-emerged as major clonotypes at 
1st relapse and persisted through 2nd line treatment with BcRi (data not shown).   
In order to investigate the functional impact of treatment on CLL T cells, we studied 
the expression of activation and exhaustion markers on T cells. We found that R-ID 
upregulates certain activation markers including IL-2 receptor (CD25) in effector 
memory T cells compared to IB. Although this increase was arithmetically small, one 
needs to consider the fact that the frequency of each major clone is relatively low; 
therefore, even though we purposely focused our analysis on well-defined functional 
T cell subpopulations, the immunophenotypic activation of anti-tumor T cell clones 
may be "diluted" within the respective subpopulation. It is also possible that CLL T 
cells undergo phenotypic changes within tissue TMEs as well as the PB.42  
Considering that T cell dysfunction in CLL manifests in a defective ability to form 





immune synapse formation capability.18, 19 We found that, in contrast to FCR, BcRi 
improved immune synapse function and the recognition of tumor B cells. 
Interestingly, for the R-ID case which was studied beyond 3 months, this synapse 
restoration correlated with the depth of clinical response, however definite 
conclusions cannot be drawn as this was a single case. Improvement in immune 
synapse formation could be attributed to treatment-induced reduction in tumor load 
(as the T cell defect has been shown to be tumor-induced)18, 19; however, the fact 
that this did not occur following FCR, the only treatment that led to complete 
remissions, argues in favor of a BcRi-specific effect on T cell function. Admittedly, the 
number of cases analyzed for immune synapse formation was limited, due to the 
substantial number of T cells required for all assays performed in this study. Notably, 
our results are in keeping with a previous report studying the immunomodulatory 
impact of FCR and R-IB.43  
Overall, NGS immunogenetics showed that BcRi retain T cell clones which can 
expand in parallel to deepening clinical response and possibly contribute to it. This is 
further corroborated by phenotypic and functional bioassays that demonstrate 
concurrent T cell activation and improvement in synapse recognition of tumor cells. 
Taken together, this study provides a rationale for designing future combinatorial 
therapeutic strategies aiming to boost anti-tumor immune responses. In support of 
this, recent studies have described the ability of both ibrutinib and idelalisib to 
enhance chimeric antigen receptor T-cell efficacy in CLL.44, 45 Future identification of 
the relevant CLL-associated antigens may eventually pave the way for stratified 
treatments by means of engineered T cells or peptide vaccines, especially if these 
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Figure 1. A. Schematic representation of the study cohort. The FCR treatment group 
included 9 patients sampled prior to treatment and 3 months after completion of 6 FCR 
cycles. The IB group included 15 patients [12 receiving IB as 1st line treatment and 3, coming 
from the FCR treatment group, who relapsed after FCR and received IB as 2nd line treatment 
(the latter in dark grey)]. The R-ID group included 10 patients [7 receiving R-ID as 1st line 
treatment, 2 coming from the FCR treatment group who relapsed after FCR and received R-
ID as 2nd line treatment (in light grey without outline), and 1 coming from the IB treatment 
group who relapsed on IB and received R-ID as 2nd line treatment (in light gray with outline)]. 
Sampling timepoints for the IB and R-ID treatment groups were 3 months, 9 months and at 
best clinical response while on continuous BcRi treatment. For 6 patients (underlined by a 
dashed line, IB, n=3; R-ID, n=3), bone marrow samples were also obtained in addition to PB 
prior to BcRi treatment. All samples were analyzed by NGS. Immune synapse bioassays were 
performed for 14 patients (marked with a dot; FCR, n=3; IB, n=6; R-ID, n=5). Flow cytometry 
for activation/exhaustion markers was performed for 8 patients (marked with a light grey 
dot IB, n=4; R-ID, n=4).  B. Schematic representation of the NGS pipeline. TRBV-TRBD-TRBJ 
gene rearrangements were RT-PCR amplified and subjected to paired-end NGS (MiSeq, 
Illumina), as previously described.29 Instead of arbitrarily excluding low-frequency 
clonotypes, which may lead to underestimation of repertoire diversity, both the read-
stiching algorithm as well as IRProfiler apply strict quality rules in order to maximize the 
accuracy of results.  
 
Figure 2. T cell clonality significantly increases after treatment with FCR and over 
treatment with R-ID. The % cumulative frequency of the major clonotypes is depicted 
overtime per treatment group in a box-whisker fashion. 
 
Figure 3. FCR results in T cell repertoire renewal, whereas BcRi treatment retains pre-
treatment T cell clones. Venn diagrams are used to depict the overlap between the T cell 
repertoire pre-treatment and at the 3-month timepoint per treatment group, concerning (A) 
only the major T cell clonotypes, and (B) the total T cell repertoire. Overlap was calculated as 
the percentage of clonotypes of the pre-treatment repertoire which persisted at 3 months. 





Jaccard index, defined as the size of the intersection divided by the size of the union of the 
two sample sets [Jaccard similarity coefficient, J(A,B)=|A∩B|/(|A|+|B|-|A∩B|)], is plotted 
on the (y) axis. Comparisons concern the repertoire of each patient (dot) pre/3 months, 
pre/9 months and pre/deepest response, per treatment group. The median overlap (vertical 
line) remains practically the same over time for the IB and R-ID group, and significantly 
higher than for FCR.   
 
Figure 4. "Public" and CLL-specific clonotypes. Of the 563 major clonotypes of the CLL 
cohort, 41 (7%) were found in other entities ("public") or shared among different CLL 
patients ("CLL-specific")  
 
Figure 5. Clonality analysis overtime, excluding "public" clonotypes. (A) Clonality 
significantly increases after treatment with FCR and over treatment with R-ID. The % 
cumulative frequency of the major clonotypes is depicted overtime per treatment group in a 
box-whisker fashion, after having excluded clonotypes that were also found in other 
entities/healthy individuals ("public" clonoypes). (B) Persisting clonotypes expand overtime, 
especially in the case of R-ID. Fishplots depicting how the frequency of each persisting 
major clonotype changes in relation to the pre-treatment timepoint, again having excluded 
"public" clonotypes. Three characteristic cases of patients receiving R-ID and IB are depicted 
in the left and right column, respectively. Each ribbon represents a CLL-specific major 
clonotype which persists in all three timepoints over treatment (sequentially: pre-treatment, 
at 3 months, 9 months, and deepest response) and the thickness of the ribbon at each 
timepoint corresponds to the clonotype's relative frequency. The remaining repertoire is 
shown in white for all cases.  
 
Figure 6. BcRi treatment restores F-actin immunological synapses between CLL tumor cells 
and autologous T cells. Untreated CLL tumor cells (CMAC dyed, blue) were conjugated with 
autologous negatively selected CD3+ T cells from CLL patient samples obtained prior 
initiation of treatment (pre) and 3 months post treatment. All conjugates per treatment 
time-point were acquired using a confocal microscope. Quantitative image analysis (relative 
recruitment index [RRI])  was used for the calculation of F-actin (red) and perforin (green) 





(IB) (n=6) and (C) R-idelalisib (R-ID) (n=5) treated samples. Bar charts show the mean RRI 
values of all T-cell/B-cell CLL conjugates per treatment ± SEM. The confocal images show 
representative T-cell/B-cell conjugates for all treatments. Original magnification of 
immunofluorescence images ×63. (D) F-actin RRI analysis over deepening response for two 
patients on BcRi. Each dot corresponds to the mean RRI values ± SEM for treatment time-
point. Differences between pre- and post-treatment samples were assessed by Wilcoxon 















SUPPLEMENTAL TABLE  1. Study cohort demographics and clinicobiological information  
   
Patient ID Date of birth Sex 


































Patient 1 15/08/1966 M I A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV2-5*01 IGHD3-3*02 IGHJ4*02 100.00 
Patient 2 16/05/1952 M II B 46,XY, del(17)(p13)[3]/45, X,-Y[3]/46,XY[24]         POSITIVE POSITIVE A536G NEGATIVE IGHV5-51*01 IGHD2-2*01 IGHJ4*01 100.00 
Patient 3 01/01/1953 F II B 46,XX,t(14;22)(q34;q11)[6]/46XX[22] NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE       IGHV3-48*02 IGHD1-26*01 IGHJ1*01 98.96 
Patient 4 22/07/1952 M I A   NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*04 IGHD3-10*01 IGHJ6*02 100.00 
Patient 5 24/04/1948 F IV C 46,XX[20] POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 100.00 
Patient 6 05/02/1944 M 0 A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-48*01 IGHD2-2*01 IGHJ6*02 100.00 
Patient 7 30/10/1953 M II B 46,XY,-17,+mar[5]/46,XY[20] POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE   POSITIVE IGHV4-39*01 IGHD3-3*01 IGHJ5*02 100.00 
Patient 8 15/05/1955 M 0 A 46XY[25]           NEGATIVE   NEGATIVE IGHV3-30*03 IGHD6-6*01 IGHJ6*02 100.00 
Patient 9  25/05/1967 F 0 A 
45,X,add(X)(q?),del(1)(p?),add(8)(p?), 
add(9)(p?),add(12)(p?),-13,del(14)(q?), 
-17,add(19)(q?),+mar [4] NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE POSITIVE           100.00 
Patient 10 03/05/1952 M II A   POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE A316T NEGATIVE IGHV2-26*01 IGHD5-18*01 IGHJ4*02 100.00 
Patient 11 30/10/1964 M II A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-33*01 IGHD3-9*01 IGHJ4*02 100.00 
Patient 12 17/02/1932 F 0 A No metaphases NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE NEGATIVE           100.00 
Patient 13 8/5/1938 M I A 46, XY POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE               
Patient 14 24/04/1961 F 0 A   NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE           100.00 
Patient 15 12/11/1946 F 0 A   POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE           98.00 
Patient 16 21/06/1971 F I A 46,XX[25] NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE     NEGATIVE IGHV3-20*01 IGHD3-22*01 IGHJ3*02 94.10 
Patient 17 10/09/1965 F II B 46,XX[20]     NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*06 IGHD3-16*02 IGHJ1*01 99.30 
Patient 18 29/11/1960 M II B 46,XY,del(13)(q12q14)[2]/46,XY[18] POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-2*02 IGHD6-19*01 IGHJ4*02 100.00 
Patient 19 01/01/1941 M II A 46,XY[20] POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*01 IGHD6-19*01 IGHJ5*02 100.00 
Patient 20 25/03/1940 M 0 A 46,XY,del(11)(q23)[16]/46,XY[4] POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-11*01 IGHD2-15*01 IGHJ6*02 100.00 
Patient 21 05/07/1942 M I A 47,XY+12[12]/46,XY[3] NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV7-4-1*02 IGHD6-19*01 IGHJ4*02 100.00 
Patient 22 13/08/1943 M 0 A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE G818A NEGATIVE IGHV4-61*01 IGHD3-3*01 IGHJ5*02 100.00 
Patient 23 08/03/1935 F 0 A 46,ΧΧ[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-11*01 IGHD3-10*01 IGHJ6*02 100.00 
Patient 24 22/11/1942 F 0 A   POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE           98.64 
Patient 25 12/02/1938 M II B 47,XY,+12[11]/46,XY[14] NEGATIVE NEGATIVE     NEGATIVE POSITIVE G524C NEGATIVE IGHV1-69*09 IGHD3-22*01 IGHJ5*01 99.70 
Patient 26 24/10/1951 M IV C 46,XY[20] POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*01 IGHD2-2*02 IGHJ6*02 100.00 
Patient 27 11/04/1952 M 0 A 46,XY,del(13)(q13q21)[5]/46,XY[18]         NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*01 IGHD3-10*01 IGHJ6*03 100.00 
Patient 28 01/01/1945 F 0 A 
46,XX,del(11)(q23),add(12)(p13)[3]/46,sdl, 
+6,-8,add(17)(p13)[14]/46,XX[8] NEGATIVE NEGATIVE   POSITIVE NEGATIVE     NEGATIVE IGHV1-2*02 IGHD5-5*01 IGHJ4*02 100.00 
* Patients who were included in the immune synapse bioassays are denoted in red font 





 #type of cell, TCR=1, BCR=2 
 cell_type=1 
 # minimum length of initial sequence (unpaired read) 
 min_sequence_length=150 
 #nucleotides with lower quality are considered bad 
 quality_limit=14 
 #accepted sequence mean quality equal or higher of selected value  
 mean_quality=20 
 # percentage of nts that can have low_quality  
 percentage_low_quality=0.15 
 # minimum percentage of acceptable unidentified nucleotides (N)  
 percentage_Ns=0.01 








 #final_min_length of the final stitched sequence 
 joined_min_length=200 
  #percentage of nts that can have low_quality in joined sequence 
 joined_perc_low_quality=0.07 
 #nucleotides with lower quality are considered bad in joined sequence 
 joined_quality_limit=20 
 #length to look for, before CDR3-end anchor 
 estimated_CDR3_length=75 




   
SUPPLEMENTAL TABLE 4. Shared major T cell clonotypes across CLL patients   
 
AA Junction Pt1 Pt2 Pt6 Pt7 Pt8 Pt9 Pt10 Pt11 Pt13 Pt14 Pt15 Pt16 Pt17 Pt18 Pt19 Pt20 Pt21 Pt22 Pt23 Pt24 Pt25 Pt27 Pt28 Pt32 Pt33 Pt35 Pt36 Pt40 Pt41 Pt43 Pt45 
CASSEESTLLNYGYTF                       5.10         30.87                             
CAISEKGGRDYGYTF                                   6.10           5.14              
CASSFGGTGNQPQHF                         6.40                             5.04       
CASSPPWTGELFF                                           8.14    5.06            
CASARGGNQPQHF             5.03       7.33                                         
CASSQDQGNNQPQHF                     12.03                                       5.09 
CASSIDSPPSEKLFF                           9.82                         5.20        
CASSESGGNQPQHF                         5.08         9.33                       5.05  
CASSLGPGANVLTF     5.08   13.89                                                     
CASSPGTGYTF                             12.95 5.09                              
CASSSANYGYTF       18.44               5.08 15.95 7.27 6.89       10.75               5.11        
CASSSDSKIGELFF                           24.14 5.08                                 
CASSIFGELFF   15.03 8.88                                                         
CASSTTGGDGYTF                     8.53       5.07             5.26                  
CASTPGDTIYF                 5.05             5.95                              
CSVDPSGTGGEGYTF     17.57         5.09        5.06 5.03                                   
CSVGSGAGGQSNYGYTF         13.98                 5.05                                   
CSVGSGGTNEKLFF     13.20                             5.04 5.69                         
CSVGTGGTNEKLFF   5.16                             6.48 5.03     5.23         5.07     5.88     
CSVLPRQGREDGYTF                               5.09  23.19                           
CASSPSRNTEAFF                               6.83            5.91                 
CASSLEGDRPQHF           6.00       6.02                5.09                         
CASSWDKSYGYTF                             6.63               5.09                 
CASSGTNANYGYTF     17.12         5.09                                              
CASSFGRGYEKLFF                         6.40     5.27  5.02   6.11                       
CASSPSTGTIYGYTF       5.39   5.48             5.99                                     
CASSPVTGTGSYGYTF                         5.19 21.44                         5.08        
CASSYGDSYGYTF 5.65                     5.13                                       
CASSYQTGAAYGYTF   9.50                   11.84                                       
CASSLAPGTTNEKLFF           5.21                       11.10                           
* For across-patient comparisons, the concatenated sum of unique clonotypes from all PB samples of the same patient was considered.                          
   For each clonotype, the highest frequency among one patient’s samples is reported here. 
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Suppl. Fig. 2. A. The TRBV gene repertoire remains stable at the 3-month timepoint in all treatment groups. The % frequency of the 9 most frequent TRBV genes pre-tretament and at the 
3-month timepoint per treatment group is depicted. B. The TRBV gene repertoire remains stable over time for the IB and R-ID groups. The % frequency of the 9 most frequent TRBV genes 
pre-treatment, at 3 months, 9 months and deepest clinical response is depicted for the IB and R-ID group.  
FCR IB R-ID 
pre 3mo pre 3mo 9mo Deepest 
response 
pre 3mo 9mo Deepest 
response 






































FCR IB R-ID 
pre 3mo pre 3mo 9mo Deepest 
response 
pre 3mo 9mo Deepest 
response 






































FCR IB R-ID 
pre   3mo pre 3mo 9mo Deepest 
response 
pre 3mo 9mo Deepest 
response 







































Suppl. Fig. 3D 
Increase of clonality post-treatment results from the expansion of the major clonotypes. A, B, C: Frequency (%) of the 10, 20 and 50 most expanded clonotypes (dots) per sample 
overtime, respectively. Clonotypes of the same patient are represented by the same color. The vertical line represents the median value. D: Clonotype frequency against rank 
plot for the IB and R-ID pre- and +9mo post-treatment. 
Suppl. Fig. 4. R-ID increases the expression of activation markers on effector memory T cells as compared to IB treatment. Each panel (A, B, C, D) shows how treatment affects the expression of 
an activation marker on a specific T-cell subpopulation for a pair of an R-ID and an IB-treated patient. (A: CD69 expression on CD4+ EM T cells; B: CD38 expression on CD8+ EM T cells; C: CD38 
expression on CD8+ TEMRA cells; and, D: CD25 expression on CD8+ TEMRA cells) 
SUPPLEMENTAL TABLE  1. Study cohort demographics and clinicobiological information  
   
Patient ID Date of birth Sex 


































Patient 1 15/08/1966 M I A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV2-5*01 IGHD3-3*02 IGHJ4*02 100.00 
Patient 2 16/05/1952 M II B 46,XY, del(17)(p13)[3]/45, X,-Y[3]/46,XY[24]         POSITIVE POSITIVE A536G NEGATIVE IGHV5-51*01 IGHD2-2*01 IGHJ4*01 100.00 
Patient 3 01/01/1953 F II B 46,XX,t(14;22)(q34;q11)[6]/46XX[22] NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE       IGHV3-48*02 IGHD1-26*01 IGHJ1*01 98.96 
Patient 4 22/07/1952 M I A   NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*04 IGHD3-10*01 IGHJ6*02 100.00 
Patient 5 24/04/1948 F IV C 46,XX[20] POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-30-3*01 IGHD3-10*01 IGHJ4*02 100.00 
Patient 6 05/02/1944 M 0 A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-48*01 IGHD2-2*01 IGHJ6*02 100.00 
Patient 7 30/10/1953 M II B 46,XY,-17,+mar[5]/46,XY[20] POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE   POSITIVE IGHV4-39*01 IGHD3-3*01 IGHJ5*02 100.00 
Patient 8 15/05/1955 M 0 A 46XY[25]           NEGATIVE   NEGATIVE IGHV3-30*03 IGHD6-6*01 IGHJ6*02 100.00 
Patient 9  25/05/1967 F 0 A 
45,X,add(X)(q?),del(1)(p?),add(8)(p?), 
add(9)(p?),add(12)(p?),-13,del(14)(q?), 
-17,add(19)(q?),+mar [4] NEGATIVE POSITIVE NEGATIVE NEGATIVE POSITIVE POSITIVE           100.00 
Patient 10 03/05/1952 M II A   POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE A316T NEGATIVE IGHV2-26*01 IGHD5-18*01 IGHJ4*02 100.00 
Patient 11 30/10/1964 M II A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-33*01 IGHD3-9*01 IGHJ4*02 100.00 
Patient 12 17/02/1932 F 0 A No metaphases NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE NEGATIVE           100.00 
Patient 13 8/5/1938 M I A 46, XY POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE               
Patient 14 24/04/1961 F 0 A   NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE           100.00 
Patient 15 12/11/1946 F 0 A   POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE           98.00 
Patient 16 21/06/1971 F I A 46,XX[25] NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE     NEGATIVE IGHV3-20*01 IGHD3-22*01 IGHJ3*02 94.10 
Patient 17 10/09/1965 F II B 46,XX[20]     NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*06 IGHD3-16*02 IGHJ1*01 99.30 
Patient 18 29/11/1960 M II B 46,XY,del(13)(q12q14)[2]/46,XY[18] POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-2*02 IGHD6-19*01 IGHJ4*02 100.00 
Patient 19 01/01/1941 M II A 46,XY[20] POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*01 IGHD6-19*01 IGHJ5*02 100.00 
Patient 20 25/03/1940 M 0 A 46,XY,del(11)(q23)[16]/46,XY[4] POSITIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-11*01 IGHD2-15*01 IGHJ6*02 100.00 
Patient 21 05/07/1942 M I A 47,XY+12[12]/46,XY[3] NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV7-4-1*02 IGHD6-19*01 IGHJ4*02 100.00 
Patient 22 13/08/1943 M 0 A 46,XY[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE G818A NEGATIVE IGHV4-61*01 IGHD3-3*01 IGHJ5*02 100.00 
Patient 23 08/03/1935 F 0 A 46,ΧΧ[20] NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV3-11*01 IGHD3-10*01 IGHJ6*02 100.00 
Patient 24 22/11/1942 F 0 A   POSITIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVE           98.64 
Patient 25 12/02/1938 M II B 47,XY,+12[11]/46,XY[14] NEGATIVE NEGATIVE     NEGATIVE POSITIVE G524C NEGATIVE IGHV1-69*09 IGHD3-22*01 IGHJ5*01 99.70 
Patient 26 24/10/1951 M IV C 46,XY[20] POSITIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*01 IGHD2-2*02 IGHJ6*02 100.00 
Patient 27 11/04/1952 M 0 A 46,XY,del(13)(q13q21)[5]/46,XY[18]         NEGATIVE NEGATIVE   NEGATIVE IGHV1-69*01 IGHD3-10*01 IGHJ6*03 100.00 
Patient 28 01/01/1945 F 0 A 
46,XX,del(11)(q23),add(12)(p13)[3]/46,sdl, 
+6,-8,add(17)(p13)[14]/46,XX[8] NEGATIVE NEGATIVE   POSITIVE NEGATIVE     NEGATIVE IGHV1-2*02 IGHD5-5*01 IGHJ4*02 100.00 
* Patients who were included in the immune synapse bioassays are denoted in red font 





 #type of cell, TCR=1, BCR=2 
 cell_type=1 
 # minimum length of initial sequence (unpaired read) 
 min_sequence_length=150 
 #nucleotides with lower quality are considered bad 
 quality_limit=14 
 #accepted sequence mean quality equal or higher of selected value  
 mean_quality=20 
 # percentage of nts that can have low_quality  
 percentage_low_quality=0.15 
 # minimum percentage of acceptable unidentified nucleotides (N)  
 percentage_Ns=0.01 








 #final_min_length of the final stitched sequence 
 joined_min_length=200 
  #percentage of nts that can have low_quality in joined sequence 
 joined_perc_low_quality=0.07 
 #nucleotides with lower quality are considered bad in joined sequence 
 joined_quality_limit=20 
 #length to look for, before CDR3-end anchor 
 estimated_CDR3_length=75 




   
SUPPLEMENTAL TABLE 4. Shared major T cell clonotypes across CLL patients   
 
AA Junction Pt1 Pt2 Pt6 Pt7 Pt8 Pt9 Pt10 Pt11 Pt13 Pt14 Pt15 Pt16 Pt17 Pt18 Pt19 Pt20 Pt21 Pt22 Pt23 Pt24 Pt25 Pt27 Pt28 Pt32 Pt33 Pt35 Pt36 Pt40 Pt41 Pt43 Pt45 
CASSEESTLLNYGYTF                       5.10         30.87                             
CAISEKGGRDYGYTF                                   6.10           5.14              
CASSFGGTGNQPQHF                         6.40                             5.04       
CASSPPWTGELFF                                           8.14    5.06            
CASARGGNQPQHF             5.03       7.33                                         
CASSQDQGNNQPQHF                     12.03                                       5.09 
CASSIDSPPSEKLFF                           9.82                         5.20        
CASSESGGNQPQHF                         5.08         9.33                       5.05  
CASSLGPGANVLTF     5.08   13.89                                                     
CASSPGTGYTF                             12.95 5.09                              
CASSSANYGYTF       18.44               5.08 15.95 7.27 6.89       10.75               5.11        
CASSSDSKIGELFF                           24.14 5.08                                 
CASSIFGELFF   15.03 8.88                                                         
CASSTTGGDGYTF                     8.53       5.07             5.26                  
CASTPGDTIYF                 5.05             5.95                              
CSVDPSGTGGEGYTF     17.57         5.09        5.06 5.03                                   
CSVGSGAGGQSNYGYTF         13.98                 5.05                                   
CSVGSGGTNEKLFF     13.20                             5.04 5.69                         
CSVGTGGTNEKLFF   5.16                             6.48 5.03     5.23         5.07     5.88     
CSVLPRQGREDGYTF                               5.09  23.19                           
CASSPSRNTEAFF                               6.83            5.91                 
CASSLEGDRPQHF           6.00       6.02                5.09                         
CASSWDKSYGYTF                             6.63               5.09                 
CASSGTNANYGYTF     17.12         5.09                                              
CASSFGRGYEKLFF                         6.40     5.27  5.02   6.11                       
CASSPSTGTIYGYTF       5.39   5.48             5.99                                     
CASSPVTGTGSYGYTF                         5.19 21.44                         5.08        
CASSYGDSYGYTF 5.65                     5.13                                       
CASSYQTGAAYGYTF   9.50                   11.84                                       
CASSLAPGTTNEKLFF           5.21                       11.10                           
* For across-patient comparisons, the concatenated sum of unique clonotypes from all PB samples of the same patient was considered.                          
   For each clonotype, the highest frequency among one patient’s samples is reported here. 
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Suppl. Fig. 2. A. The TRBV gene repertoire remains stable at the 3-month timepoint in all treatment groups. The % frequency of the 9 most frequent TRBV genes pre-tretament and at the 
3-month timepoint per treatment group is depicted. B. The TRBV gene repertoire remains stable over time for the IB and R-ID groups. The % frequency of the 9 most frequent TRBV genes 
pre-treatment, at 3 months, 9 months and deepest clinical response is depicted for the IB and R-ID group.  
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Suppl. Fig. 3D 
Increase of clonality post-treatment results from the expansion of the major clonotypes. A, B, C: Frequency (%) of the 10, 20 and 50 most expanded clonotypes (dots) per sample 
overtime, respectively. Clonotypes of the same patient are represented by the same color. The vertical line represents the median value. D: Clonotype frequency against rank 
plot for the IB and R-ID pre- and +9mo post-treatment. 
Suppl. Fig. 4. R-ID increases the expression of activation markers on effector memory T cells as compared to IB treatment. Each panel (A, B, C, D) shows how treatment affects the expression of 
an activation marker on a specific T-cell subpopulation for a pair of an R-ID and an IB-treated patient. (A: CD69 expression on CD4+ EM T cells; B: CD38 expression on CD8+ EM T cells; C: CD38 
expression on CD8+ TEMRA cells; and, D: CD25 expression on CD8+ TEMRA cells) 
